- Shares of cell therapy firm Athersys (ATHX -56.4%) nosedive after its MultiStem treatment for ulcerative colitis (UC) fails to show a meaningful benefit after eight weeks following a single administration in UC patients who have not responded to other therapies in a Phase 2 clinical trial.
- The primary efficacy endpoints were a change in endoscopic score from baseline as measured by modified Baron score at eight weeks and the change in Mayo rectal bleeding subscore from baseline at four and eight weeks.
- At four weeks, the proportion patients responding to the therapy was much greater than placebo but the benefit was offset by declines in a minority of MultiStem-treated patients.
- 16-week data, including the impact of second round dosing for a subset of patients, is still being evaluated.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs